

8-11-00

A

08/10/00

Jc85 U.S. PTO

**UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)***(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
04558/044001

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTSBox Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

COMPOSITE REVERSE OSMOSIS MEMBRANE AND METHOD FOR PRODUCING THE SAME

and invented by:

Masahiko HIROSEIf a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 16 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☐ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☐ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

Jc873 U.S. PTO
09/636226

08/10/00

**22511**

PATENT TRADEMARK OFFICE

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
04558/044001

Total Pages in this Submission

Application Elements (Continued)

3. ☐ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal Number of Sheets _____
- b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
- a. ☒ Newly executed (original or copy) ☐ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (identical to computer copy)
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing

☐ First Class ☒ Express Mail (Specify Label No.): EL521606752US

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
04558/044001

Total Pages in this Submission

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Additional Enclosures (please identify below):

Associate Power of Attorney

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	11	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	2	- 3 =	0	x \$78.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$690.00
OTHER FEE (specify purpose) Assignment					\$40.00
TOTAL FILING FEE					\$730.00

- ☒ A check in the amount of \$730.00 to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0591 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Signature

Jonathan P. Osha, Reg. No. 33,986
ROSENTHAL & OSHA L.L.P.
700 Louisiana Street, Suite 4550
Houston, Texas 77002

Dated: August 10, 2000

Telephone: (713) 228-8600
Facsimile: (713) 228-8778

cc:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)Applicant(s): **Masahiko HIROSE**

Docket No.

04558/044001

Serial No.

Filing Date
August 10, 2000

Examiner

Group Art Unit

JCS73 U.S. PRO
09/06/2000

08/10/00

Invention: **COMPOSITE REVERSE OSMOSIS MEMBRANE AND METHOD FOR PRODUCING THE SAME**

I hereby certify that the following correspondence:

Application

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

August 10, 2000*(Date)*Wendy L. Hippe*(Typed or Printed Name of Person Mailing Correspondence)*Wendy L. Hippe*(Signature of Person Mailing Correspondence)*EL521606752US*("Express Mail" Mailing Label Number)*

Note: Each paper must have its own certificate of mailing.

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)Applicant(s): **Masahiko HIROSE**

Docket No.

04558/044001

Serial No.

Filing Date
August 10, 2000

Examiner

Group Art Unit

Invention: **COMPOSITE REVERSE OSMOSIS MEMBRANE AND METHOD FOR PRODUCING THE SAME**

I hereby certify that the following correspondence:

Assignment*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

August 10, 2000*(Date)*Wendy L. Hippe*(Typed or Printed Name of Person Mailing Correspondence)*Wendy L. Hippe*(Signature of Person Mailing Correspondence)*EL521606752US*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**j-973 U.S. PTO
09/636226
08/10/00

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: **COMPOSITE REVERSE OSMOSIS MEMBRANE AND
METHOD FOR PRODUCING THE SAME**

APPLICANTS: **Masahiko HIROSE**

"EXPRESS MAIL" Mailing Label Number: EL521606752US
Date of Deposit: August 10, 2000



22511

PATENT TRADEMARK OFFICE

COMPOSITE REVERSE OSMOSIS MEMBRANE AND METHOD FOR PRODUCING THE SAME

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The present invention relates to a composite reverse osmosis membrane for selectively separating components in a liquid mixture and a method for producing the same. More specifically, the present invention relates to a composite reverse osmosis membrane having a high rejection
10 property provided by a polyamide-based skin layer (referred to also as an active layer or a thin layer) on a porous support and, a method for producing such a composite reverse osmosis membrane.

2. Description of the Prior Art

15 Conventionally, a composite reverse osmosis membrane where a skin layer (active layer or a thin layer) for selective separation is formed on a porous support is known as a reverse osmosis membrane having a structure different than that of an asymmetric reverse osmosis membrane. One such example is a composite reverse osmosis membrane having a polyamide skin
20 layer formed by interfacial polymerization between polyfunctional aromatic amine and polyfunctional aromatic acid halide on a porous support (e.g., JP 55-147106 A, JP 62-121603 A, JP 63-218208 A and JP 2-187135 A).

Some of the conventional composite reverse osmosis membranes have excellent desalination performance, water permeability performance and ionic
25 substance-separation performance. However, the conventional composite reverse osmosis membranes do not have sufficient rejections for nonelectrolyte organic compounds such as isopropyl alcohol (IPA). Furthermore, the conventional composite reverse osmosis membranes do not have sufficient rejections for substances that are not dissociated at the pH
30 range where they are normally used (e.g., boron). IPA is a substance that is widely used in the semiconductor industry and the like, and boron is a problematic substance in the conversion of seawater to freshwater. Therefore, development of a composite reverse osmosis membrane capable of separating these substances at high rejections is desirable.

35

SUMMARY OF THE INVENTION

Embodiments of the present invention provide a composite reverse

osmosis membrane that has excellent desalination performance, water permeability performance and ionic substance-separation performance and is capable of separating nonelectrolyte organic compounds and nondissociative substances at the pH range where these composite reverse osmosis membranes are normally used (hereinafter, referred to also as "general pH range nondissociative substances") at a high rejection, and a method for producing the membrane.

In one aspect, the present invention relates to a composite reverse osmosis membrane including a porous support and a polyamide skin layer formed on the porous support, wherein the polyamide skin layer is formed by reacting an aromatic compound having at least two reactive amino groups with a polyfunctional acid halide compound having at least two reactive acid halide groups, and the polyamide skin layer contains bromine.

Such a composite reverse osmosis membrane of the present invention has excellent desalination performance, water permeability performance and ionic substance-separation performance and is capable of separating nonelectrolyte organic compounds such as IPA and general pH range nondissociative substances such as boron with high rejections.

In some embodiments of the composite reverse osmosis membrane of the present invention, bromine contained in the polyamide skin layer may be present in the form of bromine atoms or ions. The polyamide skin layer contains bromine, but can also contain other substances. However, when the polyamide skin layer has only chlorine, the rejection of nonelectrolyte organic compounds and general pH range nondissociative substances is not sufficiently improved. In one embodiment of the composite reverse osmosis membrane of the present invention, it is preferable that the aromatic compound portion of the polyamide skin layer has bromine. For example, the bromine atom substitutes for a hydrogen atom so as to be bound to a carbon atom of the aromatic ring of the aromatic compound.

In some embodiments of the composite reverse osmosis membrane of the present invention, it is preferable that the ratio (Br/N) of the number of the bromine atoms (Br) to the nitrogen atoms (N) is not less than 0.1 and not more than 1.0. When this ratio is 0.1 or more, the nonelectrolyte organic compounds and the general pH range nondissociative substances can be separated at a higher rejection. When the ratio is 1.0 or less, the nonelectrolyte organic compounds and the general pH range nondissociative substances can be separated at a higher rejection, while the flux is not too low

and the operational pressure is not too high, leading to economical advantages. A more preferable range of the ratio is not less than 0.15 and not more than 0.7, and a most preferable range is not less than 0.2 and not more than 0.5. In the specification, "flux" refers to a volume (m^3) of solution that permeates the membrane a day per m^2 of the area of one surface of the membrane. "Rejection" is expressed by Equation (1) below:

$$\text{Rejection (\%)} = (1 - (\frac{\text{the concentration of the permeate solution}}{\text{the average concentration of the feed solution}})) \times 100 \quad (1)$$

In some embodiments of the composite reverse osmosis membrane of the present invention, the IPA rejection at a temperature of 25 °C, a pH of 6.5, and an operational pressure of 1.5MPa is at least 98.5%, when a 0.3wt% IPA aqueous solution is used as the feed solution. When the IPA rejection is at least 98.5%, the IPA concentration in the permeate water can be sufficiently reduced.

In some embodiments of the composite reverse osmosis membrane of the present invention, the salt rejection at a temperature of 25 °C, a pH of 6.5 and a flux of $0.6\text{m}^3/\text{m}^2 \cdot \text{day}$ is at least 99%, when a 3.5wt% salt water containing 5ppm of boron is used as the feed solution, and the boron rejection is at least 85% under those conditions. Bromine is present at about 4 to 5mg/l in the seawater. In general, when the conversion from seawater to freshwater is performed by using a reverse osmosis membrane, a recovery ratio (the amount of the permeate water/the amount of the feed water) of 40% is obtained. When the boron rejection is 85% or more in operation at a recovery ratio of 40%, the concentration of boron in the permeate water is 0.7 to 0.9mg/l when the concentration of boron in the feed seawater is 4 to 5mg/l. This can be further reduced to a sufficiently low level for drinking water. More preferably, the boron rejection is 88% or more (further more preferably 90% or more). In this case, the concentration of boron in the permeate water is 0.6 to 0.7mg/l. This embodiment can maintain a sufficiently low concentration of boron for drinking water, even if the performance is degraded by aging of the membrane and so on.

In another aspect, the invention relates to a method for producing a composite reverse osmosis membrane including forming a polyamide skin layer on a porous support by reacting an aromatic compound having at least two reactive amino groups with a polyfunctional acid halide compound having at least two reactive acid halide groups, and treating the polyamide skin layer with a free chlorine aqueous solution containing bromine compound.

In some embodiments, the concentration of free chlorine in the free chlorine aqueous solution is 1 to 100mg/l. When it is 1mg/l or more, the rejection of the resultant membrane for the nonelectrolyte organic compounds and the general pH range nondissociative substances is further improved.

- 5 When it is 100mg/l or less, the flux of the resultant membrane is acceptable. It is more preferable that the concentration of free chlorine is in the range from 5 to 50mg/l.

- 10 It is preferable that the concentration of bromine in the free chlorine aqueous solution is in the range from 0.5 to 100mg/l. When it is 0.5mg/l or more, the rejection is further improved. When it is 100mg/l or less, the flux is prevented from being reduced. It is more preferable that the concentration of bromine is in the range from 1 to 50mg/l.

- 15 The free chlorine aqueous solution containing bromine compound can be prepared by, for example, dissolving a bromine compound and free chlorine in water. The bromine compound is not limited in any specific compound, as long as it can dissolve in water. Examples of the bromine compound include sodium bromide, potassium bromide, calcium bromide, magnesium bromide, ammonium bromide, lithium bromide, cadmium bromide, germanium
20 bromide, cobalt bromide, strontium bromide, cesium bromide, tungsten bromide, iron bromide, tellurium bromide, copper bromide, barium bromide, manganese bromide, hydrogen bromide or the like. Among these, a bromine compound of an alkali metal or a bromine compound of an alkaline earth metal is preferable, and a bromine compound of an alkali metal is more preferable.

- 25 The pH of the free chlorine aqueous solution is, for example, in the range from about 4 to 11. It is preferable that the pH is 4 or more, because free chlorine is prevented from becoming less soluble. It is preferable that the pH is 11 or less, because bromine can be added to the polyamide skin layer more effectively. The pH is preferably in the range from 4 to 6.8, and is most
30 preferably from 5 to 6.5.

Such a free chlorine aqueous solution containing bromine compound can be prepared, for example, by adding free chlorine to water that already contains bromine, such as seawater or well water and, if necessary, adjusting the pH to the desired range.

- 35 In the method for producing a composite reverse osmosis membrane of the present invention, the technique for the treatment process is not specifically limited. For example, it can be performed by immersing the

polyamide skin layer in the free chlorine aqueous solution containing bromine compound, applying the free chlorine aqueous solution containing bromine compound to the polyamide skin layer, or the like. In addition, it is preferable that the treatment is performed under pressure because of its processing efficiency. For example, the treatment can be performed by passing the free chlorine aqueous solution containing bromine compound through the polyamide skin layer on porous support under pressure.

In the method of the present invention, it is preferable that a reduction in the flux of the composite reverse osmosis membrane by this treatment is at least 10% based on the flux before the treatment. The reduction of the flux is preferably not less than 20% and not more than 80%, and most preferably not less than 25% and not more than 70%. When the reduction of the flux is, for example, 90% or less, there is no concern that the operational pressure of the composite reverse osmosis membrane becomes too high. This is economically advantageous.

As described above, the composite reverse osmosis membrane of the present invention has excellent desalination performance, water permeability performance and ionic substance-separation performance, and can separate nonelectrolyte organic compounds and substances that are not dissociated at the pH range where the composite reverse osmosis membrane is normally used at a high rejection. This composite reverse osmosis membrane is suitable for production of ultrapure water, desalination of seawater or brackish water, or the like. Moreover, the composite reverse osmosis membrane of the present invention can be used to remove or recover contaminants or effective substances contained in industrial waste water such as dyed waste water or electroplating waste water, which causes environmental contamination. Thus, the composite reverse osmosis membrane of the present invention can contribute to the efforts to stop the waste water from being discharged. Moreover, in the field of food industry and so on, the composite reverse osmosis membrane of the present invention can be used for concentration of effective components, water treatment such as removal of toxic components of tap water or sewage water. In particular, in the production of ultrapure water, it is possible to remove IPA contained in a feed solution at a high rejection. In the desalination of seawater, it is not only possible to remove total dissolved solids (TDS) in the seawater, but also it is possible to remove boron, which is hard to remove because it is not ionized at the general pH range, at a high rejection, so that drinking water can be

produced with one step of reverse osmosis membrane treatment.

These and other advantages of the present invention will become apparent to those skilled in the art upon reading and understanding the following detailed description.

5

DESCRIPTION OF THE PREFERRED EMBODIMENTS

A composite reverse osmosis membrane of the present invention is produced, for example, by reacting an aromatic compound having at least two reactive amino groups with a polyfunctional acid halide having at least two reactive acid halide groups so as to form a polyamide skin layer on a porous support and treating the polyamide skin layer on the porous support with a free chlorine aqueous solution containing bromine compound. In this application, bromine is used to denote bromine atom or ion instead of bromine molecule.

15 The aromatic compound having at least two reactive amino groups (hereinafter, referred to also as "polyfunctional amine") is not limited to a specific compound, and can be, for example, m-phenylene diamine, p-phenylene diamine, 1,3,5-triaminobenzene, 1,2,4-triaminobenzene, 3,5-diaminobenzoic acid, 2,4-diaminotoluene, 2,4-diaminoanisole, amidol, 20 xylylene diamine, or the like. Preferably, m-phenylene diamine, p-phenylene diamine, or triaminobenzene can be used. Among these, m-phenylene diamine or triaminobenzene are more preferable.

In the present invention, a bromine atom is added to the polyamide skin layer. This addition of a bromine atom can be performed either before or after the reaction with the polyfunctional acid halide compound. However, it is preferable to add a bromine atom after the reaction because of its reactivity with the polyfunctional acid halide compound. A chlorine atom may be added to the polyamide skin layer, but is not necessary.

Further, these aromatic polyfunctional amines can be used in combination with aliphatic or alicyclic polyfunctional amines. Examples of such aliphatic polyfunctional amines include ethylene diamine, propylene diamine, and tris(2-aminoethyl) amine. Examples of such alicyclic polyfunctional amines include 1,3-diaminocyclohexane, 1,2-diaminocyclohexane, 1,4-diaminocyclohexane piperazine, 2,5-dimethyl 30 piperazine, and 4-aminomethyl piperazine.

The polyfunctional acid halide (hereinafter, referred to also as "acid halide") is not specifically limited, and can be, for example, aromatic, aliphatic,

or alicyclic polyfunctional acid halides. Preferably, aromatic polyfunctional acid halides can be used.

5 Examples of the aromatic polyfunctional acid halides include trimesic acid chloride, terephthalic acid chloride, isophthalic acid chloride, biphenyl dicarboxylic acid chloride, naphthalene dicarboxylic acid dichloride, benzene trisulfonic acid chloride, benzene disulfonic acid chloride, and chlorosulfonyl benzene dicarboxylic acid chloride. Among these, monocyclic aromatic compounds are preferable.

10 Examples of the aliphatic polyfunctional acid halides include propane tricarboxylic acid chloride, butane tricarboxylic acid chloride, pentane tricarboxylic acid chloride, glutaryl halide, and adipoyl halide.

15 Examples of the alicyclic polyfunctional acid halides include cyclopropane tricarboxylic acid chloride, cyclobutane tetracarboxylic acid chloride, cyclopentane tricarboxylic acid chloride, cyclopentane tetracarboxylic acid chloride, cyclohexane tricarboxylic acid chloride, tetrahydrofuran tetracarboxylic acid chloride, cyclopentane dicarboxylic acid chloride, cyclobutane dicarboxylic acid chloride, cyclohexane dicarboxylic acid chloride, and tetrahydrofuran dicarboxylic acid chloride.

20 The porous support is not limited to a specific type, as long as it can support the polyamide skin layer. For example, polyarylethersulfone such as polysulfone and polyether sulfone, polyimide, polyvinylidene fluoride, or the like can be used. Above all, a porous supporting membrane made of polysulfone or polyarylethersulfone is preferred because of its chemical, mechanical and thermal stability. This porous support generally has a
25 thickness of about 25 to 125 μ m, preferably about 40 to 75 μ m, but the thickness is not necessarily limited thereto.

Next, the polyamide skin layer based on cross-linked polyamide is formed on a porous support by interfacial polymerization between the polyfunctional amine component and the acid halide component. For
30 example, a solution containing the polyfunctional amine component is applied onto a porous support to form a first layer, and then a solution containing the acid halide component is applied onto the first layer to form a second layer on the first layer. Thus, interfacial polycondensation occurs so as to form a thin membrane (polyamide skin layer) made of cross-linked polyamide on the
35 porous support.

The solution containing the polyfunctional amine further can contain a small amount of polymer such as polyvinyl alcohol, polyvinyl pyrrolidone,

polyacrylic acid or the like or polyhydric alcohol such as sorbitol, glycerin or the like to facilitate the production of the membrane or to improve the performance of the resultant composite reverse osmosis membrane.

Furthermore, a compound having a solubility parameter (described in
5 JP8-224452A) of 8 to 14 (cal/cm³)^{1/2} can be added to the solution containing the polyfunctional amine component or the solution containing the acid halide component or both, for the purpose of increasing the flux. The solubility parameter refers to an amount defined by $(\Delta H/V)^{1/2}$ (cal/cm³)^{1/2}, where the molar evaporative heat of a liquid is ΔH cal / mol, and the molar volume is V
10 cm³/mol. Examples of a substance having such a solubility parameter include alcohols, ethers, ketones, esters, halogenated hydrocarbons, and sulfur-containing compounds, and specific examples thereof are described in JP 8-224452A.

The amine salt described in JP 2-187135A, for example a salt of
15 tetraalkyl ammonium halide or trialkyl amine and an organic acid can also be added to the solution containing polyfunctional amine or the solution containing an acid halide component or both, because such salt facilitates production of the membrane, improves the absorptivity of the amine solution to the support, and accelerates the condensation reaction.

20 The solution containing polyfunctional amine or the solution containing an acid halide component or both can contain a surfactant such as sodium dodecyl benzene sulfonate, sodium dodecyl sulfate, sodium lauryl sulfate or the like. These surfactants have the effect of improving the wettability and facilitate the absorption of the solution containing
25 polyfunctional amine to the porous support.

In order to accelerate the polycondensation reaction at the interface, it is useful to add sodium hydroxide or tribasic sodium phosphate, which can remove hydrogen halide produced in the interfacial reaction, to the solution containing polyfunctional amine or the solution containing an acid halide
30 component or both, or to use an acylation catalyst or the like as a catalyst.

The concentrations of the acid halide and the polyfunctional amine in the solution containing acid halide and the solution containing polyfunctional amine are not specifically limited. The concentration of the acid halide generally is 0.01 to 5wt%, preferably 0.05 to 1wt%, and the concentration of
35 the polyfunctional amine generally is 0.1 to 10wt%, preferably 0.5 to 5wt%.

In this manner, the porous support is coated with the solution containing polyfunctional amine, and then it is coated with the solution

containing a polyfunctional acid halide compound. Thereafter, extra solution is removed, then it is heated for drying generally at about 20 to 150°C, preferably at about 70 to 130°C for about 1 to 10 minutes, preferably about 2 to 8 minutes, so as to form a thin water permeable membrane made of cross-linked polyamide. The thickness of this thin membrane generally is about 0.05 to 2μm, preferably about 0.10 to 1μm.

A laminate (a composite membrane) where the polyamide skin layer is formed on the porous support is then treated with a free chlorine aqueous solution containing bromine compound. As described above, it is preferable to perform this treatment under pressure. This pressure is in the range, for example, from 0.1 to 20MPa, preferably 0.2 to 10MPa, and more preferably 0.5 to 6MPa.

Thus, the composite reverse osmosis membrane of the present invention is produced. It is confirmed, for example, by electron spectroscopy analysis (ESCA) that the polyamide skin layer in the composite reverse osmosis membrane of the present invention contains bromine.

Examples

Next, the present invention will be described more specifically by way of examples and comparative examples.

Example 1

An aqueous solution containing m-phenylene diamine (3wt%), sodium lauryl sulfate (0.25wt%), triethylamine (2wt%) and camphor sulfonic acid (4wt%) was applied to a porous support (polysulfone-based ultrafiltration membrane). Thereafter, extra aqueous solution was removed so that a layer of the aqueous solution was formed on the support. Afterwards, an isooctane solution containing trimesic acid chloride (0.1wt%) and isophthalic acid chloride (0.15wt%) was applied onto this layer, and then was held in an oven at 120°C for 3 minutes so that a thin polymer membrane (polyamide skin layer) was formed on the porous support. Thus, a composite membrane was obtained. In this composite membrane, the average thickness of the porous support was 50μm, and the average thickness of the polyamide skin layer was 0.2μm. In the meantime, free chlorine (20mg/l) and sodium bromide (10mg/l, the amount of bromine was 7.8mg/l) were dissolved in pure water so as to prepare a free chlorine aqueous solution containing bromine compound (pH around 5.2). This solution was passed through the composite membrane at an operational pressure of 1.5MPa for 30 minutes so that the intended

composite reverse osmosis membrane was obtained.

When the performance of this composite reverse osmosis membrane was evaluated at 25°C, pH 6.5, and an operational pressure of 1.5MPa, using a 0.3wt% IPA aqueous solution as the feed solution, the IPA rejection was 99.1% and the flux was $0.3\text{m}^3/\text{m}^2 \cdot \text{day}$. The reduction in the flux for this membrane was 50%, when compared with that of Comparative Example 1, which will be described later. When this composite reverse osmosis membrane was analyzed by ESCA for the constituent elements, the ratio (Br/N) of the bromine atoms (Br) to the nitrogen atoms (N) was 0.3.

Comparative Example 1

An aqueous solution containing m-phenylene diamine (3wt%), sodium lauryl sulfate (0.25wt%), triethylamine (2wt%) and camphor sulfonic acid (4wt%) was applied to a porous support (polysulfone-based ultrafiltration membrane). Thereafter, extra aqueous solution was removed so that a layer of the aqueous solution was formed on the support. Furthermore, an isooctane solution containing trimesic acid chloride (0.1wt%) and isophthalic acid chloride (0.15wt%) was then applied onto this layer. The porous support was then held in an oven at 120°C for 3 minutes so that a thin polymer membrane (polyamide skin layer) was formed on the porous support. Thus, a composite reverse osmosis membrane was obtained. In this composite reverse osmosis membrane, the average thickness of the porous support and the average thickness of the polyamide skin layer were the same as those of the composite membrane of Example 1. In the meantime, free chlorine was dissolved in a concentration of 20mg/l in pure water to give a free chlorine aqueous solution. This solution was passed through the composite reverse osmosis membrane at an operational pressure of 1.5MPa for 30 minutes.

When this composite reverse osmosis membrane was analyzed by ESCA for the constituent elements, there was no bromine detected and the ratio (Br/N) was 0. When the composite reverse osmosis membrane was evaluated at 25°C, pH 6.5, and an operational pressure of 1.5MPa, using a 0.3wt% IPA aqueous solution as the feed solution, the IPA rejection was 98% and the flux was $0.6\text{m}^3/\text{m}^2 \cdot \text{day}$.

Examples 2, 3 and 4

Composite reverse osmosis membranes were produced in the same manner as in Example 1, except that the pH of the free chlorine aqueous

solution containing bromine compound was varied. The composite reverse osmosis membranes were analyzed for the IPA rejection and the ratio (Br/N) in the same manner as in Example 1. Table 1 shows the results.

5

Table 1

Example	pH	IPA rejection (%)	Flux ($\text{m}^3/\text{m}^2 \cdot \text{day}$)	Br/N ratio
2	6.8	98.9	0.4	0.21
3	7.4	98.6	0.5	0.17
4	10.0	98.7	0.5	0.11

Example 5

- A composite membrane was formed in the same manner as in
- 10 Example 1, and was processed into a spiral module (a diameter of 201mm and a length of 1016mm). An aqueous solution with a pH of 6.0 containing free chlorine (20mg/l) and sodium bromide (20mg/l) was passed through the spiral module at an operational pressure of 1.5MPa for 30 minutes so that a spiral module of the intended composite reverse osmosis membrane was obtained.
- 15 When the performance of this spiral module was evaluated at 25°C, pH 6.5, a flux of $0.6\text{m}^3/\text{m}^2 \cdot \text{day}$ and a recovery of 12%, using a 3.5wt% salt water containing 5ppm of boron as the feed solution, the operational pressure was 6.6MPa, the salt rejection was 99.7% and the boron rejection was 92% (the concentration of boron in the permeate water was 0.4mg/l). When this spiral
- 20 module was dismantled and the composite reverse osmosis membrane was analyzed by ESCA for the constituent elements, the ratio (Br/N) was 0.24.

Comparative Example 2

- The composite reverse osmosis membrane obtained in Comparative
- 25 Example 1 was processed into a spiral module (a diameter of 201mm and a length of 1016mm). A free chlorine aqueous solution (20mg/l, pH7) was passed through the spiral module at an operational pressure of 1.5MPa for 30 minutes. When the performance of this spiral module was evaluated at 25°C, pH 6.5, a flux of $0.6\text{m}^3/\text{m}^2 \cdot \text{day}$ and a recovery of 12%, using a 3.5wt% salt
- 30 water containing 5ppm of boron as the feed solution, the operational pressure was 5.5MPa and the salt rejection was 99.7% and the boron rejection was 84% (the concentration of boron in the permeate water was 0.9mg/l).

Example 6

Six spiral modules of Example 5 were connected in series. The performance of this series of spiral modules was evaluated at a flux of $0.5\text{m}^3/\text{m}^2 \cdot \text{day}$ and a recovery of 40%, using seawater (total dissolved solids (TDS) in the seawater of 3.7%, a concentration of boron of 4.7mg/l , a pH of 6.3 and a temperature of 19°C) as the feed solution. The results were that the operational pressure was 7.1MPa and the TDS rejection was 99.9% and the boron rejection was 94% (the concentration of boron in the permeate water was 0.3mg/l).

Comparative Example 3

Six spiral modules of Comparative Example 2 were connected in series. The performance of this series of spiral modules was evaluated under the same conditions as in Example 6. The results were that the operational pressure was 6.2MPa and the TDS rejection was 99.8% and the boron rejection was 88% (the concentration of boron in the permeate water was 0.7mg/l).

Examples 7 and 8

Composite reverse osmosis membranes were produced in the same manner as in Example 1, except that the concentration of the bromine compound contained in the free chlorine aqueous solution containing bromine compound was varied. The composite reverse osmosis membranes were analyzed for the ratio (Br/N) and the performance in the same manner as in Example 1. Table 2 shows the results.

Table 2

Example	pH	Amount of added NaBr (mg/l)	Br concentration (mg/l)	IPA rejection (%)	Flux ($\text{m}^3/\text{m}^2 \cdot \text{day}$)	Reduction in the amount of permeate water in relation to the membrane of Comparative Ex. 1 (%)
7	5.0	5	3.9	98.9	0.4	30
8	5.0	20	16	99.2	0.3	50

As seen in the above results, the composite reverse osmosis membrane of the present invention has a very high rejection of nonelectrolyte organic compounds such as IPA or general pH range nondissociative substances such

as boron.

The invention may be embodied in other forms without departing from the spirit or essential characteristics thereof. The embodiments disclosed in this application are to be considered in all respects as illustrative and not
5 limiting. The scope of the invention is indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein.

WHAT IS CLAIMED IS:

1. A composite reverse osmosis membrane comprising a porous support and a polyamide skin layer formed on the porous support,
5 wherein the polyamide skin layer is formed by reacting an aromatic compound having at least two reactive amino groups with a polyfunctional acid halide compound having at least two reactive acid halide groups, and the polyamide skin layer contains bromine.
- 10 2. The composite reverse osmosis membrane according to claim 1, wherein the aromatic compound portion of the polyamide skin layer has bromine.
3. The composite reverse osmosis membrane according to claim 1, wherein a ratio (Br/N) of the number of bromine atoms (Br) to nitrogen atoms (N) of the
15 amino groups is not less than 0.1 and not more than 1.0.
4. The composite reverse osmosis membrane according to claim 1, wherein an isopropyl alcohol rejection at a temperature of 25 °C, a pH of 6.5, and an operational pressure of 1.5MPa is at least 98.5%, when a 0.3wt% isopropyl
20 alcohol aqueous solution is used as a feed solution.
5. The composite reverse osmosis membrane according to claim 1, wherein a salt rejection at a temperature of 25 °C, a pH of 6.5, and a flux of
25 $0.6\text{m}^3/\text{m}^2 \cdot \text{day}$ is at least 99%, when a 3.5wt% salt water containing 5ppm of boron is used as a feed solution, and a boron rejection is at least 85% under those conditions.
6. A method for producing a composite reverse osmosis membrane comprising forming a polyamide skin layer on a porous support by reacting an
30 aromatic compound having at least two reactive amino groups with a polyfunctional acid halide compound having at least two reactive acid halide groups, and treating the polyamide skin layer with a free chlorine aqueous solution containing bromine compound.
- 35 7. The method for producing a composite reverse osmosis membrane according to claim 6, wherein a concentration of free chlorine in the free chlorine aqueous solution is 1 to 100mg/L.

8. The method for producing a composite reverse osmosis membrane according to claim 6, wherein a concentration of bromine in the free chlorine aqueous solution is 0.5 to 100mg/l.

5

9. The method for producing a composite reverse osmosis membrane according to claim 6, wherein a pH of the free chlorine aqueous solution is in a range from 4 to 6.8.

10 10. The method for producing a composite reverse osmosis membrane according to claim 6, wherein the treatment is performed under pressure.

11. The method for producing a composite reverse osmosis membrane according to claim 6, wherein a flux of the composite reverse osmosis
15 membrane is reduced by the treatment by at least 10% of a flux before the treatment.

ABSTRACT OF THE DISCLOSURE

A polyamide skin layer is formed on a porous support by reacting an aromatic compound having at least two reactive amino groups with a
5 polyfunctional acid halide compound having at least two reactive acid halide groups. Then, the polyamide skin layer is treated with a free chlorine aqueous solution containing bromine compound. The resultant composite reverse osmosis membrane has a high rejection for substances that are not ionized at the pH range where the membrane is normally used.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Masahiko HIROSE
Serial No.:
Filed : August 10, 2000
Title : COMPOSITE REVERSE OSMOSIS MEMBRANE AND METHOD FOR
PRODUCING THE SAME

Art Unit:
Examiner:


Assistant Commissioner for Patents
Washington, DC 20231

ASSOCIATE POWER OF ATTORNEY

Please recognize the following as associate attorneys/agents in this application:

Scott W. Hejny, Reg. No. 45,882
Y. Renee Alsandor, Reg. No. 45,883
Jeffrey S. Bergman, Reg. No. 45,925

Respectfully submitted,



Jonathan P. Osha, Reg. No. 33,986


Date: August 10, 2000

ROSENTHAL & OSHA L.L.P.
700 Louisiana Street, Suite 4550
Houston, TX 77002

Telephone: 713/228-8600
Facsimile: 713/228-8778

Date of Deposit: August 10, 2000

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Wendy L. Hippe

Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

**22511**

PATENT TRADEMARK OFFICE

下記の氏名の発明者として、私は以下の通り宣言します。
私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

上記発明の明細書（下記の欄で×印が付いていない場合は、本書に添付）は、

☐ 年 月 日に提出され、米国出願番号または特許協定条約国際出願番号を _____ とし、
（該当する場合） _____ 日に訂正されました。

私は、特許請求範囲を含む上記訂正後の明細書を検討し、同内容を理解していることをここに表明します。

私は、第37編連邦規則法典第1章56条に定義される通り、特許資格の有無について重大な意味を持つ情報を開示する義務があることを認めます。

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

COMPOSITE REVERSE OSMOSIS MEMBRANE AND
METHOD FOR PRODUCING THE SAME

the specification of which is attached hereto unless the following box is checked:

☐ was filed on _____
as United States Application Number or PCT
International Application Number
_____ and was amended on
_____ (if applicable).

I hereby state I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

Japanese Language Declaration

日本語宣言書

私は、第 35 編米国法典 119 章に基づき下記の外国でなされた特許もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張した出願の前に提出された特許または発明者証の外国出願を以下に示しています。

I hereby claim foreign priority under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

過去の外国における出願

優先権の主張

2000-081317
(Number)
(番号)

Japan
(Country)
(国名)

23 March 2000
(Day/Month/Year Filed)
(出願年月日)

☒ ☐
Yes No
はい いいえ

(Number)
(番号)

(Country)
(国名)

(Day/Month/Year Filed)
(出願年月日)

☐ ☐
Yes No
はい いいえ

(Number)
(番号)

(Country)
(国名)

(Day/Month/Year Filed)
(出願年月日)

☐ ☐
Yes No
はい いいえ

私は、第 35 編米国法典 120 章に基づいて下記の米国特許出願に授与された利益をここに主張致します。また、本出願の各請求範囲の内容が過去に第 35 編米国法典 112 章第 1 条で規定された方法で米国特許出願により開示されていない限り、過去の米国出願書提出日以降、本出願書の日本国内または特許協力条約国際提出日までの期間中に入手され、しかも第 37 編連邦規則法典 1 章 56 条で定義された特許資格の有無に重大な意味のある情報については、開示義務があることを私は認めます。

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application

(Application Serial No.)
(出願番号)

(Filing Date)
(出願日)

(Status: Patented, Pending, Abandoned)
(現況: 特許許可済み、係属中、放棄済み)

(Application Serial No.)
(出願番号)

(Filing Date)
(出願日)

(Status: Patented, Pending, Abandoned)
(現況: 特許許可済み、係属中、放棄済み)

私は本書中の私自身の知識に基づく表明が真実であり、かつ他から聞いた情報及び私が信じることを基とする表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びその他は第 18 編米国法典第 1001 章に基づき罰金、または拘禁、もしくはその両方により罰されること、またそのような故意の虚偽による表明があると出願または許可された特許の有効性が損なわれることを承知の上で上記表明をなしていることをここに宣言致します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief and believed to be true; and further that these statements were made with the knowledge that willful false statements and like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration

日本語宣言書

委任状: 下記の発明者として、私は本出願の手続きを遂行し、同出願に関連する特許商標庁との一切の取引を取り扱うため、以下の弁護士及び（または）代理人をここに指名致します。（弁護士、代理人の氏名及び登録番号を明記のこと）

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (*list name and registration number*)

Jonathan P. Osha, Reg. No. 33,986
 Alan D. Rosenthal, Reg. No. 27,833
 Richard A. Fagin, Reg. No. 39,182
 K. KaRan Reed, Reg. No. P45,036
 David E. Mixon, Reg. No. 43,809
 Adenike Adewuya, Reg. No. 42,254
 Daniel G. Nguyen, Reg. No. 42,933
 Thomas K. Scherer, Reg. No. 45,079

書類送付先

Send Correspondence to:

Jonathan P. Osha
 ROSENTHAL & OSHA L.L.P.
 700 Louisiana Street, Suite 4550
 Houston, Texas 77002

電話による直接連絡先: (名前及び電話番号)

Direct Telephone Calls to: (*name and telephone number*)

Jonathan P. Osha
 (713)228-8600

唯一または第一発明者	Full name of sole or first inventor Masahiko HIROSE
発明者の署名	Inventor's signature <i>Masahiko Hirose</i>
日付	date <i>June 20, 2000</i>
住所	Residence c/o Nitto Denko Corporation, 1-2, Shimohozumi 1-chome, Ibaraki-shi, Osaka 567-8680, JAPAN
国籍	Citizenship Japan
私書箱	Post Office Address c/o Nitto Denko Corporation, 1-2, Shimohozumi 1-chome, Ibaraki-shi, Osaka 567-8680, JAPAN